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Abstract
Summary Treatment of adult ovariectomized (OVX) rats
with strontium ranelate prevented vertebral biomechanics
degradation as a result of the prevention of bone loss and
micro-architecture deterioration associated to an effect on
intrinsic bone material quality. Strontium ranelate influ-
enced the determinants of bone strength by prevention of
ovariectomy-induced changes which contribute to explain
strontium ranelate antifracture efficacy.
Introduction Strontium ranelate effects on the determinants
of bone strength in OVX rats were evaluated.
Methods Adult female Sprague–Dawley rats were OVX, then
treated daily for 52 weeks with 125, 250, or 625 mg strontium
ranelate/kg. Bone strength, mass, micro-architecture,
turnover, and intrinsic quality were assessed.
Results Strontium ranelate prevented ovariectomy-induced
deterioration in mechanical properties with energy necessary
for fracture completely maintained vs. SHAM at 625 mg/
kg/day, which corresponds to the clinical dose. This was
related to a dose-dependent effect on bone volume, higher
trabeculae number, and lower trabecular separation in
strontium ranelate vs. OVX. Load and energy required to
induce lamella deformation were higher with strontium ranelate
than in OVX and in SHAM, indicating that the bone formed
with strontium ranelate is able to withstand greater damage
before fracture. Bone formation was maintained high or even
increased in strontium ranelate as shown by mineralizing
surfaces and alkaline phosphatase while strontium ranelate led
to reductions in deoxypyridinoline.
Conclusion Strontium ranelate administered at 625 mg/kg/day
for 52 weeks prevented OVX-induced biomechanical
properties deterioration by influencing the determinants of
bone strength: it prevented bone loss and micro-architecture
degradation in association with an effect on intrinsic bone
quality. These beneficial effects on bone contribute to explain
strontium ranelate antifracture efficacy.
Keywords Bone biomechanics . Bone intrinsic quality .
Bone micro-architecture . Ovariectomized rat .
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Introduction
Postmenopausal osteoporosis is still a major public health
problem. Until now, most efforts to reduce the risk and
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incidence of fractures have focused on therapies that either
preserve skeletal mass by inhibiting osteoclastic bone
resorption or reverse bone loss by stimulating osteoblastic
bone formation [1]. An ideal therapy for the reversal of
bone fragility would be a single therapeutic engineered to
possess both antiresorbing and bone-forming properties
[2].
Strontium ranelate, composed of two stable strontium
atoms and ranelic acid, represents a new paradigm in the
treatment of osteoporosis [3]. In phase III studies in
postmenopausal osteoporotic women, strontium ranelate
(2 g/day) reduced the risk of vertebral fracture, the risk of
nonvertebral fracture, and the risk of hip fracture over
3 years [4, 5]. It has been shown to be effective in reducing
bone loss and/or increasing bone mass and/or bone
resistance in intact mice [6], rats [7], and monkeys [8] as
well as in short-term rat models of osteopenia, including
ovariectomy-induced bone loss [9, 10] and immobilization
[11]. Furthermore, in vitro studies have shown that
strontium ranelate has an original mechanism of action
acting by reducing osteoclastic bone resorption [12, 13]
while at the same time stimulating osteoblastic bone
formation [14].
The clinical aim of an anti-osteoporotic treatment is to
decrease the risk of fracture, an event related to bone
resistance which is driven by parameters including bone
mass, bone size and shape, bone turnover, bone micro-
architecture, and intrinsic bone tissue quality including
damage accumulation [15]. Valid techniques for nonin-
vasive assessment of bone strength in human patients are
currently not available and fracture risk reduction is only
an indirect marker of bone strength. Therefore, evalua-
tion of the drug-induced effects on these variables in
animals can yield valuable insights into the underlying
mechanisms that influence the antifracture efficacy of a
therapy. The ovariectomized (OVX) rat is a well-
recognized and validated model of bone loss that closely
resembles the osteoporosis observed in postmenopausal
women [16–18]. Therefore, the current study was carried
out to evaluate the long-term bone efficacy and safety of
strontium ranelate (125, 250, and 625 mg/kg/day for
12 months) on all the determinants of bone strength in
OVX adult Sprague–Dawley rats, a relevant model of
osteoporosis, in order to better understand clinical
antifracture efficacy of this anti-osteoporotic agent. The
response to strontium ranelate was evaluated using
determinations of bone strength (using biomechanical
testing) and of the determinants influencing bone
strength: bone mass and micro-architecture (using micro-
computed tomography [μCT] and static histomorphometry),
bone turnover (using dynamic histomorphometry and bone
turnover markers), and intrinsic bone tissue quality (using
nano-indentation).
Materials and methods
Animals and treatment
The protocol for this experiment was approved by the
Institutional Animal Care and Use Committee at SkeleTech
where the study was performed. Six-month-old virgin
female Sprague–Dawley rats (Harlan Sprague Dawley,
Indianapolis, IN, USA) were randomized to treatment
groups based on body weights and ovariectomy or sham
surgery was performed. Treatment was initiated on the day
following ovariectomy or sham surgery. Animals were
individually housed in rooms with controlled temperature
and relative humidity and an alternating 12-h dark/light
photoperiod. Animals were fed PMI Certified Rodent Diet
5002 containing 0.80% calcium, 0.60% phosphorus, and
2.2 IU of vitamin D3 per gram of feed. Water was available
ad libitum.
Three OVX treatment groups (SR125, SR250, and
SR625; n=30 animals each) were administered strontium
ranelate (S12911-2, Technologie Servier, Orléans, France) at
dose levels of 125, 250, and 625 mg/kg/day. These doses
were based on previous studies demonstrating that strontium
ranelate was effective in preventing OVX-induced bone loss
and at improving bone resistance [7, 9]. Strontium ranelate
was prepared weekly as a suspension in the vehicle (0.5%
carboxymethylcellulose sodium salt, medium viscosity;
Spectrum Chemical, Gardena, CA, USA). The control
sham-operated (SHAM) group (n=24 animals) and OVX
group (n=25 animals) were administered the vehicle. All
treatments were administered daily by gavage (10 mL/kg) for
52 weeks.
During treatment, body weights were obtained weekly
and the animals were individually pair-fed according to the
average daily food consumption of the SHAM control
animals. Prior to necropsies performed on week 52, all
animals received a fluorochrome-labeling regimen on
days 16/15 and 5/4 prior to killing to deposit double
fluorochrome labels on mineralizing surfaces (calcein
green, 12 mg/kg IP). At the time of necropsy, the final
body weights were recorded and the animals were sedated
with ketamine/xylazine and then humanely killed while still
under sedation. Following killing, the uterus was removed
and weighed to verify the success of ovariectomy. The
lumbar vertebrae (L2 to L5) were then excised.
Bone mechanical properties
Biomechanical tests were performed in a blinded manner
on LV5 vertebral body specimens using an Instron
mechanical testing machine (Instron 4465 retrofitted to
5500) interfaced to a personal computer with Merlin II
machine software. For each sample, the vertebral arch,
1418 Osteoporos Int (2009) 20:1417–1428
pedicle, and cranial and caudal ends of each vertebral body
were removed using a low-speed diamond saw to obtain a
vertebral body specimen with two parallel surfaces and a
height of approximately 4 mm (width and height of the
vertebral body were measured using digital calipers). The
specimens were then placed between two platens and a load
was applied at a displacement rate of 6 mm/min until failure.
The load–displacement curve for each test was recorded: the
maximum load at failure (expressed in newtons) as well as
the yield load at the transition between the elastic and
plastic phases of the deformation were manually selected
(changes detected on the tangent). Machine software was
then used to calculate the stiffness (slope of the elastic part
of the curve, expressed in newtons per millimeter) and
total energy absorbed (total energy absorbed, expressed in
millijoules). All calculations were according to established
formulae [15].
Bone histomorphometry
Bone specimens for histomorphometry (L3) were fixed in
cold, 70% ethanol immediately after collection. After
trimming, the bone samples were dehydrated, infiltrated,
and embedded in methyl methacrylate plastic composite
[19]. L3 in the sagittal plane were sectioned at 5 and 10 μm
using a Reichert–Jung motorized rotary microtome
equipped with a tungsten carbide microtome knife. The
5-μm sections were stained with Goldner’s trichrome for
bright field microscopy and the 10-μm sections were left
unstained for epifluorescence microscopy.
Bone histomorphometry was performed using an
OsteoMeasure software program version 4.00c (OsteoMetrics,
Atlanta, GA, USA) interfaced with a Nikon Eclipse E400 light/
epifluorescent microscope and video subsystem. The sampling
site of the secondary spongiosa of the vertebral body was
performed on an area approximately 1×2mmwithin the central
portion of the vertebral body, extending dorsoventrally within
the marrow space, but excluding the endocortical surfaces.
Vigorous validation process was performed prior to the
histomorphometry measurement based on Good Laboratory
Practices requirements. In particular, only one user performed
the measurements with an intra-user precision of 0.72% for
BV/TV measurement as an example. The measurements were
performed at the middle one third of the lumbar vertebral body
and, on average, the marrow cavity of the lumbar vertebral
body is about 1.2–1.6×5–6 mm and it seems then hard to fit a
region of interest much bigger than 1×2 mm in the cancellous
bone of a rat vertebral body. The region of interest may be
smaller than usual but the results are quite representative as they
are always measured at the same place in each lumbar vertebral
body and the sample size (20 to 27) in each treatment group
added further assurance. Furthermore, this 2-D histomorpho-
metric measurement method allowed demonstrating a 49.1%
OVX-induced bone loss, in accordance with the results found
in 3-D histomorphometry, assessed by μCT. We, therefore,
consider that this method allowed validating the model of
ovariectomy and the following profound deterioration of bone
architecture and that the results obtained in strontium ranelate-
treated groups can be interpreted. Static parameters (trabecular
volume [BV/TV; percent]; trabecular number [Tb.N; number
per millimeter]; trabecular thickness [Tb.Th; micrometers];
trabecular spacing [Tb.Sp; micrometers]; osteoid volume
[OV/TV; percent]) and dynamic parameters (mineralizing
surface [MS/BS; percent]; mineral apposition rate [MAR;
micrometers per day]; bone formation rate [BFR/BS; cubic
micrometers per square micrometer per year]) were measured
in a blinded manner in cancellous bone and were calculated
according to the recommendations of the American Society
for Bone and Mineral Research committee [20].
Bone nano-indentation
Proximal and distal plateaus of L2 vertebral bodies were cut
transversally. The samples were exposed to ultrasound in
Deconnex® bath in order to remove the marrow content and
rinsed with water. The samples were embedded in poly-
methyl methacrylate and the faces of the proximal cut were
polished and finished with a 0.25-μm diamond spray. The
specimens were then hydrated in a 9 g/L NaCl solution for
16 h and nano-indentation tests were performed in wet
conditions. A Nano Hardness Tester (CSM Instruments,
Peseux, Switzerland) equipped with a three-sided pyramidal
Berkovich indenter was used. Five indentations were
performed along the center of the posterior cortex of the
vertebrae and five indentations in trabecular nodes close to
the posterior cortex. The indenter was pressed into the
specimens to a 900-nm maximum depth at a rate of 76 mN/
min. At maximum load, a 5-s holding period was imposed.
The applied load and the penetration depth were continu-
ously recorded during the loading and unloading cycle.
Hardness (H) and modulus (Eit) were directly calculated
from this load–displacement curve using the method
previously described [21, 22]. In addition, the dissipated
energy that occurred during the deformation of bone was
also estimated from this curve.
Bone microtomography
At the end of these evaluations, the embedded L2 vertebral
samples were measured by μCT. Parameters of mass and
architecture of the secondary spongiosa of the L2 vertebral
body were investigated with a high-resolution microcom-
puter tomography system (μCT 40, Scanco Medical,
Bassersdorf, Switzerland). Three-dimensional images of
L2 vertebral body were acquired with a voxel size of
20 μm in all spatial directions. The resulting gray-scale
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images were segmented using a low-pass filter to remove
noise and a fixed threshold to extract the mineralized bone
phase. The trabecular and cortical parts of the vertebrae were
separated with semi-automatically drawn contours. From the
binarized images, structural indices were assessed. Relative
bone volume (BV/TV), trabecular number (Tb.N), thickness
(Tb.Th), and separation (Tb.Sp) were calculated by measuring
directly the 3-D distances in the trabecular network. The mean
cortical thickness (Cort.Th.) was also evaluated.
Serum and urine biochemistry
Animals were sedated with a ketamine/xylazine anesthetic
for blood sampling from the retro-orbital sinus. Serum
samples were obtained on the day of surgery and again
during weeks 8, 26, and 52. The effectiveness of ovariec-
tomy was confirmed by radioimmunoassay determination
of serum levels of 17beta-estradiol (Diagnostic Products,
Los Angeles, CA, USA). To assess bone formation, serum
alkaline phosphatase (ALP) was determined colorimetrically
on a Roche Cobas Mira auto-analyzer (Roche Diagnostic
Systems, Somerville, NJ, USA). In order to assess exposure
to circulating strontium ranelate, serum concentrations of
strontium were measured at the end of the 52-week treatment
period by inductively coupled plasma atomic emission
spectrometry (Vista apparatus, Varian).
Urinary samples were collected at week 0 and again during
weeks 8, 26, and 52. Prior to urine collections, the animals
were placed in metabolic cages and deprived of food for an
overnight fast period of 18 h. Centrifuged urine samples were
measured for deoxypyridinoline (DPD) by enzyme-linked
immunosorbent assay (Quidel, San Diego, CA, USA) to
assess bone resorption. The DPD values were normalized to
the urinary creatinine, which was determined colorimetrically
on a Roche Cobas Mira auto-analyzer (Roche Diagnostic
Systems, Somerville, NJ, USA).
Statistical analyses
Results are presented as the means±standard deviations
(SD) for all parameters measured and comparisons between
groups were done using analysis of variance (ANOVA)
[23]. When an overall treatment effect was shown by
ANOVA, significant differences vs. the OVX group or the
SHAM group were evaluated using Dunnett’s multiple
comparison procedure or a Fisher test (for μCT and nano-
indentation results). For the statistical evaluation of the
nano-indentation results, a mean value of five indents was
obtained in each bone envelope for each rat and these
values were used to calculate the level of significance of the
difference between the groups.
Results
Animals
Treatment of OVX rats with 125, 250, or 625 mg/kg/day of
strontium ranelate was well-tolerated and safe as it did not
have any significant or adverse effects on animal survival,
food consumption, body weight changes, clinical signs
during the study, terminal body weights, or gross pathology
at necropsy (data not shown). Despite pair-feeding, the body
weights in all OVX animals (OVX, SR125, SR250, and
SR625) slightly increased (from 7.3% to 9.2%) compared to
the SHAM rats. However, strontium ranelate had no effect
on the body weight gain, confirming that the treatment was
well-tolerated. Success of ovariectomy was confirmed at
necropsy by the significantly decreased uterine weights and
by the lack of detectable levels of serum estradiol in all OVX
rats whatever the time point and regardless of treatment, in
contrast with SHAM rats exhibiting mean estradiol levels of
8.9±0.5 pg/mL at killing.
Serum strontium concentrations
SHAM and OVX endogenous serum strontium concentra-
tions were similar. After strontium ranelate oral administration
for 52 weeks, serum strontium concentration changes were
dose-dependent (Table 1). However, the serum strontium
concentrations increased 3.4 times between the dose levels of
125 and 625 mg/kg/day, while the given dose increased five
times. Therefore, serum strontium concentrations did not
increase proportionally to the dose administered, indicating
saturation of the strontium absorption processes.
Bone mechanical properties
Compared to SHAM animals, compressive testing of L5
vertebral bodies of OVX animals showed significantly lower
Table 1 Serum strontium concentration (in nanograms per milliliter) obtained at the end of a 52-week treatment with strontium ranelate at 125,
250, and 625 mg/kg/day in OVX rats
SHAM (n=20) OVX (n=20) SR125 (n=29) SR250 (n=26) SR625 (n=28)
37.8±16.4 55.6±58.4 2,609.9±601.6 4,594.1±1,137.4 8,999.2±2,269.9
Values represent the mean±SD
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maximal load (−31.9%, p<0.01, Table 2), stiffness (−33.3%,
p<0.01), and energy absorbed (−44.0%, p<0.05). Similarly,
the yield load was −31.5% lower (p<0.01). Strontium
ranelate-treated OVX rats showed a dose-dependent higher
maximal load (up to +24.7%, p<0.05) of the vertebral bodies
when compared to OVX controls (Fig. 1a). This was
accompanied by a complete prevention of the ovariectomy-
induced energy lost in animals treated with 625 mg/kg/day,
while stiffness in strontium ranelate-treated animals was
unchanged from the values in the OVX animals treated with
vehicle (Fig. 1b; Table 2).
Bone mass and architecture
2-D histomorphometry of the L3 lumbar vertebra
Ovariectomy exerted negative effects on cancellous bone
structural properties, evidenced by lower BV/TV, Tb.N, and
Tb.Th and higher Tb.Sp in OVX vs. SHAM groups for the
lumbar vertebra (Figs. 2 and 3). Treatment of OVX rats
with 125, 250, or 625 mg/kg/day strontium ranelate
prevented the effects of ovariectomy with significant
dose-dependent higher BV/TV and Tb.N and lower Tb.Sp
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Fig. 1 a Maximum load (in newtons) and b energy (in millijoules) of
L5 lumbar vertebra obtained by a compression test in OVX rats treated
with strontium ranelate at 125, 250, and 625 mg/kg/day for 52 weeks.
Values represent the mean±SD; n=20–27 animals per group. *p<0.05
compared to OVX control group; **p<0.01 compared to OVX control
group
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compared to OVX control (Figs. 2 and 3). Furthermore, the
mean values for Tb.Th in rats treated with 250 mg/kg/day
strontium ranelate were as much as +20.2% greater in the
lumbar vertebra vs. values in the OVX group, but statistical
significance was not achieved.
3-D histomorphometry of the L2 lumbar vertebra
In the OVX control group, BV/TV, Tb.N, and Tb.Th were
markedly and significantly decreased (−39.8%, −22.4%, and
−7.1%, respectively; Fig. 4). As a consequence, Tb.Sp was
significantly increased to +29%. The treatment by strontium
ranelate dose-dependently prevented these micro-architecture
deteriorations with a significantly higher BV/TV, Tb.N, and
Tb.Th than in OVX control animals (up to +36.3%, +12.8%,
and +7.6%, respectively, at the highest dose tested, p<0.05
to p<0.001) and a lower Tb.Sp (up to −12.5% for SR625,
p<0.001). No statistical changes of the cortical thickness were
induced by ovariectomy and by strontium ranelate as well.
Intrinsic bone tissue quality
At the level of the trabecular bone, OVX decreased all the
parameters of intrinsic bone tissue quality assessed by the
nano-indentation technique (Fig. 5). The differences be-
tween OVX and SHAM control groups were statistically
significant for hardness (−13.4%, p<0.05). In contrast,
compared to the OVX control group, all the intrinsic bone
tissue quality parameters were significantly higher in rats
treated with strontium ranelate whatever the dose level. The
highest values were systematically observed in the group
receiving SR250, +15.9% for modulus (p<0.01), +35.7% for
a b
c
e
d
Fig. 2 L3 lumbar vertebra rep-
resentative pictures of each
group (Goldner’s trichrome
staining, ×10 magnification). a
SHAM animal; b OVX animal;
c, d, and e strontium ranelate-
treated animals with 125, 250,
and 625 mg/kg/day, respectively
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hardness (p<0.001), and +18.4% for dissipated energy
(p<0.01). Furthermore, in the same strontium ranelate-treated
group, SR250, the values were also significantly higher than
in SHAM controls for hardness (+17.5%) and dissipated
energy (+11.2%). At the level of cortical bone (Fig. 5), no
significant differences between the OVX control group and
the SHAM control group were observed. However, the
hardness was significantly higher in OVX rats treated with
strontium ranelate at doses of 125 and 250 mg/kg/day
compared to OVX control group (+13.4%, p<0.05,
and +17%, p<0.01, respectively).
Bone turnover
Dynamic histomorphometry of the L3 lumbar vertebra
As expected, ovariectomy produced significantly higher
dynamic indices of bone formation in the lumbar vertebra
(Fig. 3), including bone mineralizing surfaces (MS/BS;
+128.8%) and bone formation rate normalized to bone
surface (BFR/BS; +121.2%). These changes were consis-
tent with the expected increase in bone formation that
accompanies increased bone turnover in estrogen-deficient
animals. In rats treated with strontium ranelate, MS/BS and
BFR/BS of the lumbar vertebra remained elevated at the
high turnover level observed in OVX control rats.
Serum alkaline phosphatase
Treatment of OVX animals with strontium ranelate
increased serum levels of ALP, a marker of bone formation,
dose-dependently with statistically significant increases of
30.0%, 25.9%, and 23.9% in the SR625 group at the 8-, 26-,
and 52-week time points, respectively (p<0.01 compared to
OVX; Table 3).
Urinary deoxypyridinoline
Ovariectomy resulted in increased mean levels of urinary
DPD, a biomarker of bone resorption at the 8-, 26-, and 52-
week time points (Table 3) with a maximal effect 8 weeks
after ovariectomy. In addition, there was a notable age-
related decline in this parameter that appeared to reach a
steady state by the 26-week time point (i.e., around the age
of 1-year-old). Strontium ranelate treatment reduced the DPD
levels by 20.4%, 13.9%, and 21.1% (p<0.05 compared to
OVX for SR625, Fig. 1b) in the SR125, SR250, and SR625
groups, respectively, at the 8-week time point.
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Fig. 3 L3 lumbar vertebra 2-D
histomorphometry indices in
OVX rats treated with strontium
ranelate. Values are expressed as
the mean±SD; n=20–27 animals
per group. *p<0.05 compared to
OVX; ** p<0.01 compared to
OVX
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Discussion
The results indicate that ovariectomy decreased lumbar
vertebra bone strength by altering bone mass, bone micro-
architecture, and intrinsic bone tissue quality, which is
consistent with previously published findings observed in
this model [16–18, 24–30]. In contrast, in the conditions of
this study, there were no reductions in the mechanical
strength of the midshaft femur in OVX control rats
52 weeks after ovariectomy when compared to SHAM
control rats (mean maximum load±SD=182.64±17.85 N
for OVX vs. 171.41±17.47 N for SHAM). This may be
explained by the lack of OVX-induced cortical bone loss
(no change of cortical width, data not shown) and by an
increase in cross-sectional geometries between SHAM and
OVX animals (data not shown), as previously described in
this model [31, 32]. The combination of these two effects is
consistent with the lack of differences in long bone strength
between the SHAM and OVX control groups as the
resistance to bending loads is primarily governed by the
midshaft’s geometric configuration. Therefore, the absence
of effects of ovariectomy on long bones midshaft cortical
strength preclude any interpretation in our experimental
conditions.
Compared to vehicle-treated OVX controls, the treat-
ment of OVX rats with strontium ranelate for 1 year at
doses of 125, 250, and 625 mg/kg/day was well-tolerated
and safe. These dose levels lead to mean serum strontium
concentrations which correspond, respectively, to 0.25-,
0.44-, and 0.87-fold the median serum strontium concen-
trations observed in patients administered the therapeutic
dose of 2 g/day (i.e., 10,560 ng/mL, [4]) and receiving
1,500 mg calcium/day. As illustrated in the present study,
serum strontium concentrations did not increase propor-
tionally to the dose administered (serum strontium concen-
trations increased of only 3.4 times when dose levels
increased of five times), indicating a saturation of the
strontium ranelate absorption processes when doses in-
crease. As the same transport properties that have been
developped and extensively used for studies of calcium
absorption also apply to strontium [33], it is assumed that
some portions of strontium are absorbed into blood from
the intestinal lumen via passive nonsaturable diffusion
while another portion proceeds by an active saturable
transport [34] which can explain why calcium and
strontium can compete during their absorption process.
Interestingly, this is illustrated in a recent publication [35]
where OVX rats receiving 150 mg/kg/day of strontium
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ranelate with a normal calcium diet (1.19% Ca) exhibited,
as expected, a sevenfold less serum strontium concentration
than the same dose given with a calcium-deficient diet
(0.1% Ca) due to the competition in the absorption process
of both cations. In the Fuchs et al. paper [35], when normal
calcium diet was given to OVX rats, the serum strontium
concentration obtained at 150 mg/kg/day was comparable
to the one observed in the present study at the dose of
125 mg/kg/day. Nevertheless, these concentrations repre-
sent a fourfold lower strontium concentration than the one
observed in treated patients at the therapeutic dose which
explains their lack of efficacy. It is also interesting to note
that, in this recent publication [35], strontium ranelate at
150 mg/kg/day (but administered with a calcium-deficient
diet) exhibited no efficacy in OVX rats while leading to a
higher serum strontium concentration than the efficient
dose of 625 mg/kg/day in the present paper (administered
with normal calcium diet). This confirms that no beneficial
effect on bone is possible if the amount of calcium available
from the diet is not sufficient. It is indeed described in the
literature that ovariectomy worsens the calcium deficiency-
induced hyperparathyroidism leading to decreases in bone
calcium content, bone mineral density, and bone strength
[36, 37]. Therefore, as recommended for all drugs used for
osteoporosis treatment, a normal calcium intake is neces-
sary and only serum strontium concentrations obtained in
OVX rats fed a normal calcium diet are relevant for human
therapeutic interpretation.
In the present study, at the dose of 625 mg/kg/day, leading
in OVX rats fed a normal calcium diet to serum strontium
concentration close to those observed in treated patients, the
maximum load and total energy absorbed by the vertebra
before fracture were equivalent to SHAM animals, indicating
a complete prevention of the ovariectomy-induced loss of
bone strength.
In the strontium ranelate-treated OVX rats, BV/TV
values were intermediate between those of OVX and
SHAM control groups, as indicated by the significant
difference between the BV/TV measured by 2-D and 3-D
histomorphometry and the OVX and SHAM controls. The
prevention in BV/TV values degradation was accompanied by
corresponding dose-dependent positive effects of strontium
ranelate on bone micro-architecture as evidenced by higher
Tb.N and Tb.Th. Importantly, the two different methods used
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to assess these parameters, namely, 2-D and 3-D histomorph-
ometry, led to the same results, suggesting a negligible
influence of strontium on bone μCT assessment in these
conditions. It is important to note that bone strength was
assessed at the level of the whole vertebral body; the measured
bone strength reflects both the contribution of the trabecular
and cortical compartments on bone resistance. In contrast,
micro-architecture was assessed, whatever the method used,
only at the trabecular level which can explain why the partial
effect on micro-architecture cannot totally explain the full
rescue of the biomechanical effect on bone strength.
Evaluation of the bone biomarkers and dynamic indices
of bone formation provide further insight regarding stron-
tium ranelate’s beneficial action on bone. Interestingly, the
effects on bone resorption markers of strontium ranelate
after ovariectomy combined a modest decrease in urinary
DPD (observed mainly at 625 mg/kg/day and at the 8-week
time point when ovariectomy induced the maximal
increased level of bone resorption), in line with a decreased
osteoclastic bone resorption [12, 13, 38] observed together
with a dose-dependent increase in the serum levels of ALP
in OVX animals, consistent with previous data [9]. Taken
together, these observations indicate that the ability of
strontium ranelate to prevent the ovariectomy-induced bone
loss is due to a combination of its inhibitory effects on bone
resorption and its ability to stimulate and/or maintain high
levels of bone formation. Maintaining elevated indices of
bone formation in OVX animals provides evidence for an
effect on bone formation [9, 14, 38] and the dynamic
indices of bone formation such as mineralizing surface and
bone formation rate are coherent with the bone markers
changes observed. However, cellular parameters (such as
osteoclast and osteoblast number and surface) were not
measured in this study because their changes, 52 weeks
after ovariectomy when the adult rats were more than
18 months old, were anticipated to be undetectable
compared to SHAM controls. It is indeed described in
Wronski et al. [26] that, from 150 days after ovariectomy,
osteoblast surfaces and osteoclast surfaces in OVX rats
declined to SHAM control levels. Furthermore, osteoblasts
are difficult to identify in old animals and this can result in
a high variability of the cellular parameters. Static cellular
parameters are not indicative of cellular activity and
corresponding bone formation and resorption rates. They
can only give information at a given time, without allowing
an extrapolation for the whole treatment period. In contrast,
dynamic fluorochrome-based parameters are meaningful as
they provide strong evidence for a high bone formation
rate. In OVX strontium ranelate-treated rats, fluorochrome-
based indices of bone formation were maintained high
while bone mass decrease was prevented, indicating that the
level of bone formation exceeds the level of bone
resorption.
In younger OVX rats [9], strontium ranelate decreased
histomorphometric indices of bone resorption to the levels
in SHAM animals; in contrast to this inhibitory effect on
bone resorption, osteoblast surfaces were as high in OVX
rats treated with strontium ranelate as those in control OVX
rats treated with vehicle. The positive strontium ranelate
effect on bone mass and bone micro-architecture can then
be related to the cellular effect observed in previous in vitro
and in vivo studies which indicate that strontium ranelate
acts through a dual mechanism of action [38], namely,
reduction of osteoclastic bone resorption [12, 13] and
stimulation of osteoblastic bone formation [14].
The contribution of intrinsic bone tissue quality, using
nano-indentation tests in wet conditions, was assessed at
the level of the dorsal cortex of the vertebral body and of
the trabecular nodes close to this region. Previous studies
indicated that this latter area of the vertebral body is
markedly affected by low protein regimen or treatments of
osteoporosis [21]. The results of the present study confirm
Table 3 Bone formation (ALP) and bone resorption markers (urinary DPD) in OVX rats treated with strontium ranelate
SHAM (n=20–22) OVX (n=22–25) SR125 (n=28–30) SR250 (n=27–30) SR625 (n=27–30)
ALP (IU/L) Baseline 162±22 (+1.3) 160±33 [−1.2] 159±37 (−0.6) 161±23 (+0.6) 161±42 (+0.6)
Week 8 159±26 (−0.6) 160±36 [+0.6] 156±34 (−2.5) 178±34 (+11.3) 208±35** (+30.0)
Week 26 153±24 (−3.2) 158±28 [+3.3] 156±28 (−1.3) 161±30 (+1.9) 199±47** (+25.9)
Week 52 170±33 (−5.6) 180±53 [+5.9] 182±53 (+1.1) 193±39 (+7.2) 223±48** (+23.9)
DPD (nM/mM
creatinine)
Baseline 27.7±9.9 (−17.6) 33.6±17.3 [+21.3] 36.9±33.2 (+9.8) 31.9±12.0 (−5.1) 37.0±17.6 (+10.1)
Week 8 27.5±14.9** (−74.0) 105.7±37.8 [+284.4] 84.1±27.5 (−20.4) 91.0±34.2 (−13.9) 83.4±30.4* (−21.1)
Week 26 15.4±5.4** (−49.3) 30.4±11.8 [+97.4] 30.3±8.8 (−0.3) 33.5±14.4 (+10.2) 31.5±7.1 (+3.6)
Week 52 13.6±5.0** (−66.3) 40.4±18.1 [+197.1] 38.1±15.0 (−5.7) 37.3±18.0 (−7.7) 43.1±19.3 (+6.7)
Values represent the mean±SD. The positive or negative values in parentheses beside the mean values for SHAM and SR groups indicate the
percent change vs. OVX. The values in square brackets beside the mean values for the OVX indicate the percent change vs. SHAM
*p<0.05 compared to OVX; **p<0.01 compared to OVX
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that trabecular bone intrinsic quality is affected by OVX
and that the treatment with strontium ranelate at each
investigated dose resulted in a significant higher hardness
and dissipated energy in this type of bone. Whatever the
strontium ranelate dose, these values were higher than in
SHAM controls. These results indicate that the load and
energy required to induce a given deformation of a bone
lamella are markedly increased by strontium ranelate
treatment in OVX rats. The bone tissue formed under
strontium ranelate treatment shows improved intrinsic
quality properties, suggesting that it is able to withstand
greater damage before fracture. The fact that cortical bone
is poorly affected by OVX is not surprising, since in
rodents there is little remodeling of the cortical bone and
since its vascularization is poorly developed. Furthermore,
the treatment started in mature rats in which no periosteal
apposition could be observed. However, even in these
conditions, strontium ranelate was able to increase hardness
at two dose levels. This is in line with a previous study
performed in intact rats treated during all their life with
strontium ranelate where a mild but significant effect of the
treatment was observed at the level of the cortical bone
[39].
How strontium ranelate totally prevented and even
improved the OVX-induced deterioration of intrinsic bone
tissue quality is still under investigation. Indeed, strontium
ranelate does not affect crystal properties and characteristics
as shown in vivo [40, 41]: the normal mineralization
process and the mean degree of mineralization of bone are
preserved, and when strontium takes the place of calcium,
only one calcium ion out of ten is substituted by one
strontium ion in the hydroxyapatite crystal lattice. The
majority of strontium present in bone is adsorbed onto the
surface of the crystal, in the nonapatitic hydrated layer [42].
This leads to the hypothesis that this strontium localization
in the bone tissue could potentially lead to a better cohesion
between the mineral and the protein matrix and/or to a
direct or indirect effect (through the cellular activity) on the
spatial orientation of the crystals in the lamellae or between
the lamellae themselves.
In conclusion, strontium ranelate effects on bone mass,
on trabecular micro-architecture, and on the intrinsic
properties of the material allow explaining, at the dose
level of 625 mg/kg/day, the prevention of OVX-induced
biomechanical deterioration. Long-term strontium ranelate
treatment prevents the OVX-induced deterioration of bone
mechanical properties acting on all their main determinants
in adult rats at a therapeutic equivalent human dose level.
This therapeutic effect was associated with a bone
formation rate maintained at a high level together with a
slight decrease of bone resorption. Taken together, obser-
vations reported in this study support the efficacy and the
safety of strontium ranelate and contribute to explain
strontium ranelate antifracture efficacy for the treatment of
postmenopausal osteoporosis.
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